ArticleHemaSphere2023

Correction Notice: Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.